An additional bispecific, humanized IgG1 antibody which is beneath investigation is zenocutuzumab (MCLA-128), which functions by way of two independent mechanisms of action: inhibition of HER2–HER3 signalling and elimination of tumour cells by way of ADCC. MCLA-128 functions by using a ‘dock and block’ system whereby 1 arm in the antibody bin